Global CDK 4/6 Inhibitor Drugs Market Outlook 2023-2035

The global CDK 4/6 inhibitor drugs market is anticipated to grow with a CAGR of 16.78% over the forecast period, i.e., 2022 - 2035. Factors such as the surge in the cases of breast cancer among women, followed by the rising development of combination therapies including CDK 4/6 inhibitor drugs are projected to drive the growth of the market in the coming years. Additionally, the rising advancement in drug development is also expected to boost the market growth. The market is estimated to garner a revenue of nearly USD 66.63 billion by the end of 2035, up from a revenue of about USD 9.03 billion in the year 2022.

The global CDK 4/6 inhibitor drugs market is segmented into numerous segments, which include segmentation by patient, drug type, end-user, and by region. By end user, the market is segmented into hospitals, clinics, research laboratories, and retail pharmacies. By the end of 2035, the hospital segment is anticipated to garner the largest revenue of around USD 38.18 billion, up from a revenue of close to USD 5.14 billion in the year 2022.

On the basis of region, the global CDK 4/6 inhibitor drugs market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in North America, amongst the market in all the other regions, is anticipated to garner the largest revenue of more than USD 45.96 billion by the end of 2035. Moreover, in the year 2022, the market in the region generated a revenue of over USD 6.30 billion.

Some of the prominent industry leaders in the global CDK 4/6 inhibitor drugs market that are included in our report are Novartis AG, Eli Lilly and Company, Jiangsu Hengrui Pharmaceuticals Co., Ltd., AstraZeneca plc, Celltrion, Inc, Merck & Co., Inc., Halozyme Inc. and others.

1. An Outline of the Global CDK 4/6 Inhibitor Drugs Market

1.1. Market Definition
1.2. Market Segmentation
1.3. Industry Overview

2. Assumptions & Abbreviations

3. Research Methodology & Approach

3.1. Research Process
3.2. Primary Research
3.2.1. Manufacturers
3.2.2. Suppliers/Distributors
3.2.3. End Users
3.3. Secondary Research
3.4. Market Size Estimation

4. Summary of the Report for Key Decision Makers

5. Forces of Market Constituents

5.1. Factors/drivers impacting the growth of the market
5.2. Market trends for better business practices

6. Key Market Opportunities for Business Growth7. Major Roadblocks for the Market Growth8. Regulatory Landscape9. Industry Value Chain Analysis10. Recent Developments in the Market11. Impact of COVID-1912. Epidemiology13. Treatment Guidelines for Breast Cancer14. Unmet Needs15. Product Profiling16. Drug pricing and Reimbursements17. Comparative Drug Analysis18. Drug Pipeline Analysis19. Competitive Positioning

20. Competitive Model: A Detailed Inside View for Investors

20.1. Company Market Share (2022)
20.2. Business Profile of Key Enterprise
20.2.1. Pfizer Inc.
20.2.2. Novartis
20.2.3. Eli Lilly and Company
20.2.4. Jiangshu Hengrui Pharmaceuticals Co. Ltd.

21. Global CDK 4/6 Inhibitor Drugs Market Outlook

21.1. Market Overview
21.2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
21.3. Year-on-Year (YoY) Growth Trend Analysis
21.4. Global CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
21.4.1. By Drug Type
21.4.1.1. Palbociclib, Market Value (USD Million) and CAGR, 2022-2035F
21.4.1.2. Ribociclib, Market Value (USD Million), and CAGR, 2022-2035F
21.4.1.3. Abemaciclib, Market Value (USD Million), and CAGR, 2022-2035F
21.4.1.4. Dalpiciclib, Market Value (USD Million), and CAGR, 2022-2035F
21.4.1.5. Birociclib, Market Value (USD Million), and CAGR, 2022-2035F
21.4.1.6. Lerociclib, Market Value (USD Million), and CAGR, 2022-2035F
21.4.1.7. BPI 16350, Market Value (USD Million), and CAGR, 2022-2035F
21.4.1.8. Others, Market Value (USD Million), and CAGR, 2022-2035F
21.5. Global CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
21.5.1. By Patient
21.5.1.1. PreMenopause, Market Value (USD Million) and CAGR, 2022-2035F
21.5.1.2. PostMenopausal, Market Value (USD Million) and CAGR, 2022-2035F
21.5.1.3. Others, Market Value (USD Million) and CAGR, 2022-2035F
21.6. Global CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035)
21.6.1. By End User
21.6.1.1. Hospitals, Market Value (USD Million) and CAGR, 2022-2035F
21.6.1.2. Clinics, Market Value (USD Million) and CAGR, 2022-2035F
21.6.1.3. Research Laboratories, Market Value (USD Million) and CAGR, 2022-2035F
21.6.1.4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2022-2035F
21.7. Global CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035)
21.7.1. By Geography
21.7.1.1. North America, Market Value (USD Million), and CAGR, 2022-2035F
21.7.1.2. Europe, Market Value (USD Million), and CAGR, 2022-2035F
21.7.1.3. Asia Pacific, Market Value (USD Million), and CAGR, 2022-2035F
21.7.1.4. Latin America, Market Value (USD Million), and CAGR, 2022-2035F
21.7.1.5. Middle East & Africa, Market Value (USD Million), and CAGR, 2022-2035F

22. North America CDK 4/6 Inhibitor Drugs Market Outlook

22.1. Market Overview
22.2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
22.3. Year-on-Year (YoY) Growth Trend Analysis
22.4. North America CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
22.4.1. By Drug Type
22.4.1.1. Palbociclib, Market Value (USD Million), and CAGR, 2022-2035F
22.4.1.2. Ribociclib, Market Value (USD Million), and CAGR, 2022-2035F
22.4.1.3. Abemaciclib, Market Value (USD Million), and CAGR, 2022-2035F
22.4.1.4. Dalpiciclib , Market Value (USD Million), and CAGR, 2022-2035F
22.4.1.5. Birociclib, Market Value (USD Million), and CAGR, 2022-2035F
22.4.1.6. Lerociclib, Market Value (USD Million), and CAGR, 2022-2035F
22.4.1.7. BPI 16350, Market Value (USD Million), and CAGR, 2022-2035F
22.4.1.8. Others, Market Value (USD Million), and CAGR, 2022-2035F
22.5. North America CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
22.5.1. By Patient
22.5.1.1. PreMenopause, Market Value (USD Million) and CAGR, 2022-2035F
22.5.1.2. PostMenopausal, Market Value (USD Million) and CAGR, 2022-2035F
22.5.1.3. Others, Market Value (USD Million) and CAGR, 2022-2035F
22.6. North America CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035)
22.6.1. By End User
22.6.1.1. Hospitals, Market Value (USD Million) and CAGR, 2022-2035F
22.6.1.2. Clinics, Market Value (USD Million) and CAGR, 2022-2035F
22.6.1.3. Research Laboratories, Market Value (USD Million) and CAGR, 2022-2035F
22.6.1.4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2022-2035F
22.7. North America CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035)
22.7.1. By Country
22.7.1.1. US, Market Value (USD Million), and CAGR, 2022-2035F
22.7.1.2. Canada, Market Value (USD Million), and CAGR, 2022-2035F

23. Europe CDK 4/6 Inhibitor Drugs Market Outlook

23.1. Market Overview
23.2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
23.3. Year-on-Year (YoY) Growth Trend Analysis
23.4. Europe CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
23.4.1. By Drug Type
23.4.1.1. Palbociclib, Market Value (USD Million), and CAGR, 2022-2035F
23.4.1.2. Ribociclib, Market Value (USD Million), and CAGR, 2022-2035F
23.4.1.3. Abemaciclib, Market Value (USD Million), and CAGR, 2022-2035F
23.4.1.4. Dalpiciclib , Market Value (USD Million), and CAGR, 2022-2035F
23.4.1.5. Birociclib, Market Value (USD Million), and CAGR, 2022-2035F
23.4.1.6. Lerociclib, Market Value (USD Million), and CAGR, 2022-2035F
23.4.1.7. BPI 16350, Market Value (USD Million), and CAGR, 2022-2035F
23.4.1.8. Others, Market Value (USD Million), and CAGR, 2022-203
23.5. Europe CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
23.5.1. By Patient
23.5.1.1. PreMenopause, Market Value (USD Million) and CAGR, 2022-2035F
23.5.1.2. PostMenopausal, Market Value (USD Million) and CAGR, 2022-2035F
23.5.1.3. Others, Market Value (USD Million) and CAGR, 2022-2035F
23.6. Europe CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035)
23.6.1. By End-User
23.6.1.1. Hospitals, Market Value (USD Million) and CAGR, 2022-2035F
23.6.1.2. Clinics, Market Value (USD Million) and CAGR, 2022-2035F
23.6.1.3. Research Laboratories, Market Value (USD Million) and CAGR, 2022-2035F
23.6.1.4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2022-2035F
23.7. Europe CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035)
23.7.1. By Country
23.7.1.1. UK, Market Value (USD Million), and CAGR, 2022-2035F
23.7.1.2. Germany, Market Value (USD Million), and CAGR, 2022-2035F
23.7.1.3. Italy, Market Value (USD Million), and CAGR, 2022-2035F
23.7.1.4. France, Market Value (USD Million), and CAGR, 2022-2035F
23.7.1.5. Spain, Market Value (USD Million), and CAGR, 2022-2035F
23.7.1.6. Russia, Market Value (USD Million), and CAGR, 2022-2035F
23.7.1.7. Netherlands, Market Value (USD Million), and CAGR, 2022-2035F
23.7.1.8. Rest of Europe, Market Value (USD Million), and CAGR, 2022-2035F

24. Asia Pacific CDK 4/6 Inhibitor Drugs Market Outlook

24.1. Market Overview
24.2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
24.3. Year-on-Year (YoY) Growth Trend Analysis
24.4. Asia Pacific CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
24.4.1. By Drug Type
24.4.1.1. Palbociclib, Market Value (USD Million), and CAGR, 2022-2035F
24.4.1.2. Ribociclib, Market Value (USD Million), and CAGR, 2022-2035F
24.4.1.3. Abemaciclib, Market Value (USD Million), and CAGR, 2022-2035F
24.4.1.4. Dalpiciclib , Market Value (USD Million), and CAGR, 2022-2035F
24.4.1.5. Birociclib, Market Value (USD Million), and CAGR, 2022-2035F
24.4.1.6. Lerociclib, Market Value (USD Million), and CAGR, 2022-2035F
24.4.1.7. BPI 16350, Market Value (USD Million), and CAGR, 2022-2035F
24.4.1.8. Others, Market Value (USD Million), and CAGR, 2022-203
24.5. Asia Pacific CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
24.5.1. By Patient
24.5.1.1. PreMenopause, Market Value (USD Million) and CAGR, 2022-2035F
24.5.1.2. PostMenopausal, Market Value (USD Million) and CAGR, 2022-2035F
24.5.1.3. Others, Market Value (USD Million) and CAGR, 2022-2035F
24.6. Asia Pacific CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035)
24.6.1. By End-User
24.6.1.1. Hospitals, Market Value (USD Million) and CAGR, 2022-2035F
24.6.1.2. Clinics, Market Value (USD Million) and CAGR, 2022-2035F
24.6.1.3. Research Laboratories, Market Value (USD Million) and CAGR, 2022-2035F
24.6.1.4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2022-2035F
24.7. Asia Pacific CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035)
24.7.1. By Country
24.7.1.1. China, Market Value (USD Million), and CAGR, 2022-2035F
24.7.1.2. India, Market Value (USD Million), and CAGR, 2022-2035F
24.7.1.3. Japan, Market Value (USD Million), and CAGR, 2022-2035F
24.7.1.4. South Korea, Market Value (USD Million), and CAGR, 2022-2035F
24.7.1.5. Singapore, Market Value (USD Million), and CAGR, 2022-2035F
24.7.1.6. Australia, Market Value (USD Million), and CAGR, 2022-2035F
24.7.1.7. Rest of Asia-Pacific, Market Value (USD Million), and CAGR, 2022-2035F

25. Latin America CDK 4/6 Inhibitor Drugs Market Outlook

25.1. Market Overview
25.2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
25.3. Year-on-Year (YoY) Growth Trend Analysis
25.4. Latin America CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
25.4.1. By Drug Type
25.4.1.1. Palbociclib, Market Value (USD Million), and CAGR, 2022-2035F
25.4.1.2. Ribociclib, Market Value (USD Million), and CAGR, 2022-2035F
25.4.1.3. Abemaciclib, Market Value (USD Million), and CAGR, 2022-2035F
25.4.1.4. Dalpiciclib , Market Value (USD Million), and CAGR, 2022-2035F
25.4.1.5. Birociclib, Market Value (USD Million), and CAGR, 2022-2035F
25.4.1.6. Lerociclib, Market Value (USD Million), and CAGR, 2022-2035F
25.4.1.7. BPI 16350, Market Value (USD Million), and CAGR, 2022-2035F
25.4.1.8. Others, Market Value (USD Million), and CAGR, 2022-203
25.5. Latin America CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
25.5.1. By Patient
25.5.1.1. PreMenopause, Market Value (USD Million) and CAGR, 2022-2035F
25.5.1.2. PostMenopausal, Market Value (USD Million) and CAGR, 2022-2035F
25.5.1.3. Others, Market Value (USD Million) and CAGR, 2022-2035F
25.6. Latin America CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035)
25.6.1. By End-User
25.6.1.1. Hospitals, Market Value (USD Million) and CAGR, 2022-2035F
25.6.1.2. Clinics, Market Value (USD Million) and CAGR, 2022-2035F
25.6.1.3. Research Laboratories, Market Value (USD Million) and CAGR, 2022-2035F
25.6.1.4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2022-2035F
25.7. Latin America CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035) By Country
25.7.1. Brazil, Market Value (USD Million), and CAGR, 2022-2035F
25.7.2. Mexico, Market Value (USD Million), and CAGR, 2022-2035F
25.7.3. Argentina, Market Value (USD Million), and CAGR, 2022-2035F
25.7.4. Rest of Latin America, Market Value (USD Million), and CAGR, 2022-2035F

26. Middle East & Africa CDK 4/6 Inhibitor Drugs Market Outlook

26.1. Market Overview
26.2. Market Revenue by Value (USD Million), and Compound Annual Growth Rate (CAGR)
26.3. Year-on-Year (YoY) Growth Trend Analysis
26.4. Middle East & Africa CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
26.4.1. By Drug Type
26.4.1.1. Palbociclib, Market Value (USD Million), and CAGR, 2022-2035F
26.4.1.2. Ribociclib, Market Value (USD Million), and CAGR, 2022-2035F
26.4.1.3. Abemaciclib, Market Value (USD Million), and CAGR, 2022-2035F
26.4.1.4. Dalpiciclib , Market Value (USD Million), and CAGR, 2022-2035F
26.4.1.5. Birociclib, Market Value (USD Million), and CAGR, 2022-2035F
26.4.1.6. Lerociclib, Market Value (USD Million), and CAGR, 2022-2035F
26.4.1.7. BPI 16350, Market Value (USD Million), and CAGR, 2022-2035F
26.4.1.8. Others, Market Value (USD Million), and CAGR, 2022-203
26.5. Middle East & Africa CDK 4/6 Inhibitor Drugs Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
26.5.1. By Patient
26.5.1.1. PreMenopause, Market Value (USD Million) and CAGR, 2022-2035F
26.5.1.2. PostMenopausal, Market Value (USD Million) and CAGR, 2022-2035F
26.5.1.3. Others, Market Value (USD Million) and CAGR, 2022-2035F
26.6. Middle East & Africa CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035)
26.6.1. By End-User
26.6.1.1. Hospitals, Market Value (USD Million) and CAGR, 2022-2035F
26.6.1.2. Clinics, Market Value (USD Million) and CAGR, 2022-2035F
26.6.1.3. Research Laboratories, Market Value (USD Million) and CAGR, 2022-2035F
26.6.1.4. Retail Pharmacies, Market Value (USD Million) and CAGR, 2022-2035F
26.7. Middle East & Africa CDK 4/6 Inhibitor Drugs Market Segmentation Analysis (2022-2035)
26.7.1. By Country
26.7.1.1. GCC, Market Value (USD Million), and CAGR, 2022-2035F
26.7.1.2. Israel, Market Value (USD Million), and CAGR, 2022-2035F
26.7.1.3. South Africa, Market Value (USD Million), and CAGR, 2022-2035F
26.7.1.4. Rest of Middle East & Africa, Market Value (USD Million), and CAGR, 2022-2035F

Companies Mentioned

Novartis AG
Eli Lilly and Company
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
AstraZeneca plc
Celltrion Inc
Merck & Co. Inc.
Halozyme Inc.

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5465EUR$5,550USD£4,529GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6449EUR$6,550USD£5,345GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€10388EUR$10,550USD£8,609GBP

Table of Contents

Companies Mentioned

Related Topics

Related Reports

Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions

Oncology Precision Medicine Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Cancer Targeted, Route of Administration, Type of Molecule, Drug Class, Key Geographical Regions, Leading Drug Developers and Sales Forecast

Global PARP Inhibitor Biomarkers Market by Product, by Service 1 & 2 Testing, by Application, by End-User, and By Region

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market Report 2024

CDK9 inhibitor - Pipeline Insight, 2024